Current Editions
Emerging models point to a new operating system for rare disease innovation
It is time to integrate advances from around the globe to realize the potential to treat millions who suffer from very rare conditions: a Perspective
Editor's Commentary
Data Byte
EMA’s CHMP recommends three new orphan drugs, rebuffs two FDA-approved programs
Plus positive recommendation for Moderna’s combined flu and COVID-19 mRNA vaccine
Regulation
Global experiments in rare disease innovation
Overlaps, differences in approaches in Australia, China, India, Korea, the U.K. and the U.S.
Politics, Policy & Law
U.S. investigating Chinese state support, pricing in biotech sector
International Trade Commission report could set stage for tariffs, trade restrictions
Finance
Generate IPO meets goal, but shares sink in aftermarket: Public Equity Report
Plus: Avidity spinout arrives on NASDAQ; five biotechs price follow-ons; and more
List of Western VCs tapping Japan biotech incentive continues to grow
RA Capital, The Column Group, TPG among firms selected by AMED for matching program
BioCentury ISSN 1097-7201